Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Current status of DILD in molecular targeted therapies.

Saito Y, Gemma A.

Int J Clin Oncol. 2012 Dec;17(6):534-41. doi: 10.1007/s10147-012-0494-5. Epub 2012 Nov 15. Review.

PMID:
23152005
[PubMed - indexed for MEDLINE]
2.

[Interstitial lung disease associated with chemotherapy and molecularly-targeted drug: diagnosis and management].

Saito Y, Gemma A.

Gan To Kagaku Ryoho. 2011 Dec;38(13):2531-7. Review. Japanese.

PMID:
22189216
[PubMed - indexed for MEDLINE]
3.

[Drug-induced interstitial lung disease].

Gemma A.

Gan To Kagaku Ryoho. 2008 Oct;35(10):1668-70. Japanese.

PMID:
18931568
[PubMed - indexed for MEDLINE]
4.

Drug-induced interstitial lung disease (DILD) in molecular targeted therapy.

Gemma A.

Int J Clin Oncol. 2012 Dec;17(6):533. doi: 10.1007/s10147-012-0495-4. Epub 2012 Nov 15. No abstract available.

PMID:
23152006
[PubMed - indexed for MEDLINE]
5.

Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents.

Gemma A.

J Nippon Med Sch. 2009 Feb;76(1):4-8. Review.

PMID:
19305103
[PubMed - indexed for MEDLINE]
Free Article
6.

Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.

Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M.

Semin Arthritis Rheum. 2011 Oct;41(2):256-64. doi: 10.1016/j.semarthrit.2010.11.002. Epub 2011 Feb 1.

PMID:
21277618
[PubMed - indexed for MEDLINE]
7.

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M.

J Clin Oncol. 2006 Jun 1;24(16):2549-56.

PMID:
16735708
[PubMed - indexed for MEDLINE]
Free Article
8.

Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K.

Ann Pharmacother. 2015 Jan 6. pii: 1060028014566446. [Epub ahead of print]

PMID:
25565405
[PubMed - as supplied by publisher]
9.

Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.

Chang SC, Chang CY, Chang SJ, Yuan MK, Lai YC, Liu YC, Chen CY, Kuo LC, Yu CJ.

Clin Lung Cancer. 2013 Jan;14(1):55-61. doi: 10.1016/j.cllc.2012.03.009. Epub 2012 May 17.

PMID:
22607779
[PubMed - indexed for MEDLINE]
10.

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.

Endo M, Johkoh T, Kimura K, Yamamoto N.

Lung Cancer. 2006 May;52(2):135-40. Epub 2006 Mar 29.

PMID:
16574271
[PubMed - indexed for MEDLINE]
11.

Recurrent gefitinib-induced interstitial lung disease.

Suzuki M, Asahina H, Konishi J, Yamazaki K, Nishimura M.

Intern Med. 2008;47(6):533-6. Epub 2008 Mar 17.

PMID:
18344641
[PubMed - indexed for MEDLINE]
Free Article
12.

Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.

Saito Y, Kunugi S, Suzuki Y, Narita K, Miura Y, Minegishi Y, Kimura G, Kondo Y, Azuma A, Fukuda Y, Gemma A.

Intern Med. 2013;52(2):263-7. Epub 2013 Jan 15. Review.

PMID:
23318860
[PubMed - indexed for MEDLINE]
Free Article
13.

Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.

Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1099-109. doi: 10.1007/s00280-011-1737-2. Epub 2011 Sep 13. Review.

PMID:
21913033
[PubMed - indexed for MEDLINE]
14.

Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease.

Sakuma K, Nakamura H, Nakamura T, Hoshino Y, Ueda S, Ichikawa M, Tabata C, Fujita S, Masago K, Yodoi J, Mishima M, Mio T.

Intern Med. 2007;46(23):1905-9. Epub 2007 Dec 3.

PMID:
18057762
[PubMed - indexed for MEDLINE]
Free Article
15.

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.

Makris D, Scherpereel A, Copin MC, Colin G, Brun L, Lafitte JJ, Marquette CH.

BMC Cancer. 2007 Aug 5;7:150.

PMID:
17683587
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.

Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M; Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1348-57. doi: 10.1164/rccm.200710-1501OC. Epub 2008 Mar 12.

PMID:
18337594
[PubMed - indexed for MEDLINE]
17.

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

Yoshii N, Suzuki T, Nagashima M, Kon A, Kakihata K, Gemma A.

Anticancer Drugs. 2011 Jul;22(6):563-8. doi: 10.1097/CAD.0b013e3283473f28.

PMID:
21562406
[PubMed - indexed for MEDLINE]
18.

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, Ichinose Y, Fukuoka M, Jiang H.

Anticancer Drugs. 2005 Nov;16(10):1123-8.

PMID:
16222155
[PubMed - indexed for MEDLINE]
19.

Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.

Yamada T, Moriwaki T, Matsuda K, Yamamoto Y, Sugaya A, Akutsu D, Murashita T, Endo S, Hyodo I.

Onkologie. 2013;36(4):209-12. doi: 10.1159/000349959. Epub 2013 Mar 18.

PMID:
23548971
[PubMed - indexed for MEDLINE]
20.

Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Matsuno O.

Respir Res. 2012 May 31;13:39. doi: 10.1186/1465-9921-13-39. Review.

PMID:
22651223
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk